Esophageal cancer: Recent advances in screening, targeted therapy, and management

Journal of Carcinogenesis

Volumn 13, Issue 1, 2014, Pages

  Gaur, Puja ^a   Kim, Min ^a   Dunkin, Brian ^a  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

Barrett s; Cancer stem cells; Carcinogenesis tumorigenesis; Dysplasia; Esophageal cancer; Targeted therapy

Indexed keywords

TUMOR MARKER;

BARRETT ESOPHAGUS; CANCER SCREENING; CANCER STAGING; CANCER STEM CELL; CARCINOGENESIS; DYSPLASIA; ENDOSCOPIC THERAPY; ESOPHAGUS CANCER; HUMAN; IMMUNOBIOLOGY; IMMUNOTHERAPY; MOLECULARLY TARGETED THERAPY; PATHOGENESIS; REVIEW;

EID: 85001946117     PISSN: 09746773     EISSN: 14773163     Source Type: Journal    
DOI: 10.4103/1477-3163.143720     Document Type: Review

References (46)

1. American Cancer Society. Cancer Facts and Figures 2014. Atlanta GACS; 2014. Available from: http://www.cancer.org/acs/groups/content/@research/documents/webcontent/acspc-042151.pdf. [Last accessed on 2014 Aug 02].
2. Siegel R, Naishadham D, Jemal A. Cancer statistics for Hispanics/Latinos, 2012. CA Cancer J Clin 2012;62:283-98.
3. Chandra S, Gorospe EC, Leggett CL, Wang KK. Barrett's esophagus in 2012: Updates in pathogenesis, treatment, and surveillance. Curr Gastroenterol Rep 2013;15:322.
4. Peters FP, Curvers WL, Rosmolen WD, de Vries CE, Ten Kate FJ, Krishnadath KK, et al. Surveillance history of endoscopically treated patients with early Barrett's neoplasia: Nonadherence to the Seattle biopsy protocol leads to sampling error. Dis Esophagus 2008;21:475-9.
5. Corley DA, Mehtani K, Quesenberry C, Zhao W, de Boer J, Weiss NS. Impact of endoscopic surveillance on mortality from Barrett's esophagus-associated esophageal adenocarcinomas. Gastroenterology 2013;145:312-9.e1.
6. Verbeek RE, Leenders M, Ten Kate FJ, van Hillegersberg R, Vleggaar FP, van Baal JW, et al. Surveillance of Barrett's esophagus and mortality from esophageal adenocarcinoma: A population-based cohort study. Am J Gastroenterol 2014;109:1215-22.
7. Rodriguez S, Mattek N, Lieberman D, Fennerty B, Eisen G. Barrett's esophagus on repeat endoscopy: Should we look more than once? Am J Gastroenterol 2008;103:1892-7.
8. Shakhatreh MH, Duan Z, Avila N, Naik AD, Kramer JR, Hinojosa-Lindsey M, et al. Risk of Upper Gastrointestinal Cancers in Patients With Gastroesophageal Reflux Disease After a Negative Screening Endoscopy. Clin Gastroenterol Hepatol 2014.
9. Chadwick G, Groene O, Hoare J, Hardwick RH, Riley S, Crosby TD, et al. A population-based, retrospective, cohort study of esophageal cancer missed at endoscopy. Endoscopy 2014;46:553-60.
10. Qumseya BJ, Wang H, Badie N, Uzomba RN, Parasa S, White DL, et al. Advanced imaging technologies increase detection of dysplasia and neoplasia in patients with Barrett's esophagus: A meta-analysis and systematic review. Clin Gastroenterol Hepatol 2013;11:1562-70.e1.
11. Song J, Zhang J, Wang J, Guo X, Yu S, Wang J, et al. Meta-analysis of the effects of endoscopy with narrow band imaging in detecting dysplasia in Barrett's esophagus. Dis Esophagus 2014.
12. Boerwinkel DF, Holz JA, Kara MA, Meijer SL, Wallace MB, Wong Kee Song LM, et al. Effects of autofluorescence imaging on detection and treatment of early neoplasia in patients with Barrett's esophagus. Clin Gastroenterol Hepatol 2014;12:774-81.
13. Connor MJ, Sharma P. Chromoendoscopy and magnification endoscopy for diagnosing esophageal cancer and dysplasia. Thorac Surg Clin 2004;14:87-94.
14. Leggett CL, Gorospe EC. Application of confocal laser endomicroscopy in the diagnosis and management of Barrett's esophagus. Ann Gastroenterol 2014;27:193-99.
15. Spechler SJ. Does Barrett's esophagus regress after surgery (or proton pump inhibitors)? Dig Dis 2014;32:156-63.
16. Engel LS, Chow WH, Vaughan TL, Gammon MD, Risch HA, Stanford JL, et al. Population attributable risks of esophageal and gastric cancers. J Natl Cancer Inst 2003;95:1404-13.
17. Haeri H, Mardani O, Asadi-Amoli F, Shahsiah R. Human papilloma virus and esophageal squamous cell carcinoma. Acta Med Iran 2014;52:197-200.
18. Singh S, Singh AG, Singh PP, Murad MH, Iyer PG. Statins are associated with reduced risk of esophageal cancer, particularly in patients with Barrett's esophagus: A systematic review and meta-analysis. Clin Gastroenterol Hepatol 2013;11:620-9.
19. Zhang S, Zhang XQ, Ding XW, Yang RK, Huang SL, Kastelein F, et al. Cyclooxygenase inhibitors use is associated with reduced risk of esophageal adenocarcinoma in patients with Barrett's esophagus: A meta-analysis. Br J Cancer 2014;110:2378-88.
20. Clément G, Braunschweig R, Pasquier N, Bosman FT, Benhattar J. Alterations of the Wnt signaling pathway during the neoplastic progression of Barrett's esophagus. Oncogene 2006;25:3084-92.
21. Vaninetti N, Williams L, Geldenhuys L, Porter GA, Guernsey DL, Casson AG. Regulation of CDX2 expression in esophageal adenocarcinoma. Mol Carcinog 2009;48:965-74.
22. Yang L, Francois F, Pei Z. Molecular pathways: Pathogenesis and clinical implications of microbiome alteration in esophagitis and Barrett esophagus. Clin Cancer Res 2012;18:2138-44.
23. Sims-Mourtada J, Izzo JG, Ajani J, Chao KS. Sonic Hedgehog promotes multiple drug resistance by regulation of drug transport. Oncogene 2007;26:5674-9.
24. Sims-Mourtada J, Izzo JG, Apisarnthanarax S, Wu TT, Malhotra U, Luthra R, et al. Hedgehog: An attribute to tumor regrowth after chemoradiotherapy and a target to improve radiation response. Clin Cancer Res 2006;12:6565-72.
25. Clemons NJ, Phillips WA, Lord RV. Signaling pathways in the molecular pathogenesis of adenocarcinomas of the esophagus and gastroesophageal junction. Cancer Biol Ther 2013;14:782-95.
26. Saraswati S, Alfaro MP, Thorne CA, Atkinson J, Lee E, Young PP. Pyrvinium, a potent small molecule Wnt inhibitor, promotes wound repair and post-MI cardiac remodeling. PLoS One 2010;5:e15521.
27. Jin Y, Guan S, Liu L, Sun S, Lee KH, Wei J. Anti-p16 autoantibodies may be a useful biomarker for early diagnosis of esophageal cancer. Asia Pac J Clin Oncol 2014.
28. Guan S, Liu B, Zhang C, Lee KH, Sun S, Wei J. Circulating autoantibody to CD25 may be a potential biomarker for early diagnosis of esophageal squamous cell carcinoma. Clin Transl Oncol 2013;15:825-9.
29. Ye L, Guan S, Zhang C, Lee KH, Sun S, Wei J, et al. Circulating autoantibody to FOXP3 may be a potential biomarker for esophageal squamous cell carcinoma. Tumour Biol 2013;34:1873-7.
30. Bagaria B, Sood S, Sharma R, Lalwani S. Comparative study of CEA and CA19-9 in esophageal, gastric and colon cancers individually and in combination (ROC curve analysis). Cancer Biol Med 2013;10:148-57.
31. Shimada H, Takeda A, Arima M, Okazumi S, Matsubara H, Nabeya Y, et al. Serum p53 antibody is a useful tumor marker in superficial esophageal squamous cell carcinoma. Cancer 2000;89:1677-83.
32. Bang YJ, Van Cutsem E, Feyereislova A, Chung HC, Shen L, Sawaki A, et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): A phase 3, open-label, randomised controlled trial. Lancet 2010;376:687-97.
33. Fuchs CS, Tomasek J, Yong CJ, Dumitru F, Passalacqua R, Goswami C, et al. Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): An international, randomised, multicentre, placebo-controlled, phase 3 trial. Lancet 2014;383:31-9.
34. Ku GY, Ilson DH. Emerging tyrosine kinase inhibitors for esophageal cancer. Expert Opin Emerg Drugs 2013;18:219-30.
35. Curran MA, Kim M, Montalvo W, Al-Shamkhani A, Allison JP. Combination CTLA-4 blockade and 4-1BB activation enhances tumor rejection by increasing T-cell infiltration, proliferation, and cytokine production. PLoS One 2011;6:e19499.
36. Ricci-Vitiani L, Lombardi DG, Pilozzi E, Biffoni M, Todaro M, Peschle C, et al. Identification and expansion of human colon-cancer-initiating cells. Nature 2007;445:111-5.
37. Honjo S, Ajani JA, Scott AW, Chen Q, Skinner HD, Stroehlein J, et al. Metformin sensitizes chemotherapy by targeting cancer stem cells and the mTOR pathway in esophageal cancer. Int J Oncol 2014;45:567-74.
38. Skinner HD, McCurdy MR, Echeverria AE, Lin SH, Welsh JW, O'Reilly MS, et al. Metformin use and improved response to therapy in esophageal adenocarcinoma. Acta Oncol 2013;52:1002-9.
39. Mehran R, Nilsson M, Khajavi M, Du Z, Cascone T, Wu HK, et al. Tumor endothelial markers define novel subsets of cancer-specific circulating endothelial cells associated with antitumor efficacy. Cancer Res 2014;74:2731-41.
40. Ajani JA, Barthel JS, Bentrem DJ, D'Amico TA, Das P, Denlinger CS, et al. Esophageal and esophagogastric junction cancers. J Natl Compr Canc Netw 2011;9:830-87.
41. Choi J, Kim SG, Kim JS, Jung HC, Song IS. Comparison of endoscopic ultrasonography (EUS), positron emission tomography (PET), and computed tomography (CT) in the preoperative locoregional staging of resectable esophageal cancer. Surg Endosc 2010;24:1380-6.
42. Sandha GS, Severin D, Postema E, McEwan A, Stewart K. Is positron emission tomography useful in locoregional staging of esophageal cancer? Results of a multidisciplinary initiative comparing CT, positron emission tomography, and EUS. Gastrointest Endosc 2008;67:402-9.
43. Chennat J, Konda VJ, Ross AS, de Tejada AH, Noffsinger A, Hart J, et al. Complete Barrett's eradication endoscopic mucosal resection: An effective treatment modality for high-grade dysplasia and intramucosal carcinoma-An American single-center experience. Am J Gastroenterol 2009;104:2684-92.
44. Guo HM, Zhang XQ, Chen M, Huang SL, Zou XP. Endoscopic submucosal dissection vs endoscopic mucosal resection for superficial esophageal cancer. World J Gastroenterol 2014;20:5540-7.
45. Cao Y, Liao C, Tan A, Gao Y, Mo Z, Gao F. Meta-analysis of endoscopic submucosal dissection versus endoscopic mucosal resection for tumors of the gastrointestinal tract. Endoscopy 2009;41:751-7.
46. Neuhaus H, Terheggen G, Rutz EM, Vieth M, Schumacher B. Endoscopic submucosal dissection plus radiofrequency ablation of neoplastic Barrett's esophagus. Endoscopy 2012;44:1105-13.